Study Finds Increased Heart Risks After Stopping GLP-1s

• Patients staying on GLP-1s for three years saw an 18% reduction in cardiovascular risk, but stopping for just six months raised risk by 4%, while a two-year gap increased risk by 22% compared to sustained use
• Researchers described a 'metabolic whiplash' effect where cardiovascular protection takes years to build but only half as long to lose once treatment stops
• High discontinuation rates of 36% to 81% are driven by access challenges and side effects like nausea, though Medicare will soon cover weight loss treatments and drugmakers are developing next-generation drugs with fewer side effects

Market Summary: Increased Cardiovascular Risks After Discontinuing GLP-1 Medications

Key Findings

A Washington University School of Medicine study published in BMJ Medicine reveals significant cardiovascular risks when patients discontinue GLP-1 diabetes and weight-loss medications. The research tracked over 333,000 adults with Type 2 diabetes over three years, with most using Novo Nordisk's Ozempic.

Critical Data Points

• Continuous use: 18% reduction in cardiovascular risk over three years
• Six-month gap: 4% increased risk versus sustained treatment
• Two-year gap: 22% elevated risk compared to continuous use

The study demonstrates "metabolic whiplash," where cardiovascular protection built over years can be reversed in half that time after discontinuation.

Market Implications

The findings underscore a significant challenge for GLP-1 manufacturers, particularly Novo Nordisk and Eli Lilly. Current discontinuation rates range from 36% to 81%, driven by access issues, cost barriers, and side effects including nausea and vomiting.

The research emphasizes that GLP-1s require long-term commitment rather than short-term use, which has implications for:

• Prescription patterns and patient counseling protocols
• Medicare coverage expansion for weight-loss treatments
• Generic competition from companies like Hims & Hers pursuing compounded versions

Industry Response

Drugmakers are developing next-generation treatments with improved side effect profiles to address discontinuation rates. The FDA approved semaglutide (Wegovy/Ozempic's active ingredient) in 2024 for reducing cardiovascular events in adults with heart disease and obesity.

Study author Dr. Ziyad Al-Aly emphasized that maintaining treatment "shouldn't be an afterthought," highlighting the need for better side effect management and improved access to sustain the drugs' cardiovascular benefits.